MedTrace Logo

Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis

NCT00126139 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2007-05-03

No results posted yet for this study

Summary

The purpose of the present prospective, randomized, double-blind, double dummy controlled multicenter pilot study is to investigate whether abciximab, compared with aspirin, is able to reduce the rate of recurrent ischemic strokes before and during carotid endarterectomy \[CEA\] (primary endpoints); and the degree of carotid stenosis, number of microembolic signal (MES) counts, number of ischemic infarcts at diffusion weighted imaging (DWI) and amount of intraluminal thrombus at pathological examination (secondary endpoints) in patients with ischemic stroke due to a \>50% carotid stenosis who will undergo CEA.

Conditions

Interventions

DRUG

Abciximab

Sponsors & Collaborators

  • Schweizerische Herzstiftung

    collaborator OTHER

  • Eli Lilly and Company

    collaborator INDUSTRY

  • University of Zurich

    lead OTHER

Principal Investigators

  • Ralf W. Baumgartner, MD · University Hospital of Zurich, Department of Neurology, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Completion
2005-05-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00126139 on ClinicalTrials.gov